Molecule provides early clue to prostate cancer metastasis

By / 25th of January, 2017

RAISED levels of a tiny molecule in the bloodstream have been linked with prostate cancer metastasis, potentially helping researchers detect the spread of the disease sooner.

A multi-institutional research team led by the University of Adelaide in South Australia has found that a certain microRNA molecule promoted the metastasis of prostate cancer cells.

The study showed how miR-194 promoted cancer metastasis by inhibiting a key protein called SOCS2, which suppresses the spread of cancer cells.

Lead researcher Luke Selth from the University of Adelaide’s Dame Roma Mitchell Cancer Research Laboratories said the findings created opportunities for new prediction methods and treatments.

“We previously identified a microRNA (miR-194) that was elevated in the bloodstream of patients who experienced a poor outcome following surgery,” he said.

“By studying the level of miR-194 in the blood at an early stage of disease, it now makes it possible to identify the patients that are likely to metastasise or who have already experienced metastasis that would not have been picked up by the scanning technologies that we currently have.

“The second significant thing about this new study is we could potentially develop a drug that could inhibit miR-194 and that drug could be used to treat patients by reducing the rate of metastasis.”

According to the Australian Institute of Health and Welfare there were about 18,000 new cases of prostate cancer in Australia last year and almost 3400 deaths.

img - industries_health_prostate cancer pathway_P1The microRNA molecule miR-194 promotes cancer metastasis by inhibiting a protein called SOCS2, which suppresses the spread of cancer cells.

Dr Selth said prostate cancer only killed men after they metastasised from the prostate.

He said the identification of markers could save lives if doctors were able to use them predict the likelihood of prostate cancer spreading at an early stage.

The research team is currently testing this idea using larger patient groups to validate their findings and test whether inhibiting miRNA in the lab could suppress the spread of cancer.

“The idea is to develop a test where if you have high levels of miR-194 in your blood and were likely to experience metastasis, then you could undergo more aggressive treatment strategies,” Dr Selth said.

The international research team included members from the University of Michigan, Vancouver Prostate Centre, the Mayo Clinic and Johns Hopkins University.

The work was funded by the National Health and Medical Research Council of Australia, the Prostate Cancer Foundation (USA), the Freemasons Foundation Centre for Men’s Health, the Prostate Cancer Foundation of Australia and Movember.

The research titled MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2 was published in the journal Cancer Research.

Dr Selth’s original research on miR-194 was published in the British Medical Journal of Cancer.

South Australia’s capital Adelaide has three long-standing public universities, Flinders UniversityUniversity of South Australia and the University of Adelaide, each of which are consistently rated highly in the international higher education rankings.

Key contacts

Dr Luke Selth Prostate Cancer Foundation Research Fellow The University of Adelaide Dame Roma Mitchell Cancer Research Laboratories, Freemasons Foundation Centre for Men's Health
61 08 8222 3618 luke.selth@adelaide.edu.au www.adelaide.edu.au